8-K: Apyx Medical: Renuvion Study Shows Skin Quality Improvements

Apyx Medical announced new clinical data demonstrating Renuvion's positive impact on skin quality, showing increased elastin and high patient satisfaction.

Summary

• Apyx Medical Corporation has announced new clinical data from a prospective study evaluating Renuvion helium plasma radiofrequency technology.
• The study, published in Plastic and Reconstructive SurgeryGlobal Open, provides human tissue evidence of Renuvion's effects on biological markers of skin quality.
• Key findings at Day 180 showed a 30% increase in elastin fiber density and a 55% increase in elastin staining intensity in treated tissue.
• Inflammation was reduced by 34% in treated tissue compared to controls, indicating a healthier tissue environment.
• Human tissue analysis revealed a 27% increase in elastin expression, consistent with pro-regenerative biologic response and favorable dermal remodeling.
• No significant fibrosis, abnormal vascularization, or epithelial disruption was observed.
• 100% of participants reported visible aesthetic improvement, high satisfaction, and would recommend the procedure.
• Participants also reported noticeable improvements in skin elasticity, radiance, and youthfulness.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, highlighting strong clinical data that supports the efficacy and patient satisfaction of Renuvion technology.

Positives

• 100% of participants reported improvement in physicianand patient-assessed aesthetic scores.
• 100% of participants reported high satisfaction with treatment outcomes and would recommend the procedure.
• 100% of participants reported noticeable improvements in skin elasticity, radiance, and youthfulness.
• Treated tissue showed a 30% increase in elastin fiber density and a 55% increase in elastin staining intensity.
• Treated tissue demonstrated a 34% reduction in inflammation compared to untreated control tissue.
• Human tissue analysis showed a 27% increase in elastin expression, indicating pro-regenerative biologic response and favorable dermal remodeling.
• No significant fibrosis, abnormal vascularization, or epithelial disruption was observed in treated tissue.
• The study provides direct human histological evidence supporting observed clinical benefits.

Negatives

• The study involved a small sample size of six participants who completed the Day 180 visit.
• The study was a single-arm, post-market study, which may have limitations in establishing causality compared to randomized controlled trials.

Risks

• The Company faces risks related to the regulatory environment, including obtaining requisite approvals from the FDA and other governmental bodies.
• Sudden or extreme volatility in commodity prices and availability, including supply chain disruptions, could impact the Company.
• Changes in general economic, business, or demographic conditions or trends could affect performance.
• Changes in and effects of the geopolitical environment may impact the Company.
• The Company may incur liabilities and costs from pending or threatened litigations, claims, disputes, or investigations.
• Other risks are described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and other SEC filings.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it highlights the potential for Renuvion to be integrated into comprehensive aesthetic procedures, particularly following liposuction, suggesting a positive outlook for the technology's adoption.

Management Comments

• These findings provide important new evidence supporting the biological basis for the clinical benefits observed with Renuvion.
• For years, surgeons have seen the clinical benefits of Renuvion in tissue contraction and have observed improvements in the quality of the overlying skin.
• This study provides direct human histological evidence supporting those observations, demonstrating meaningful changes in elastin and inflammation at the tissue level.
• We believe this research adds an important new dimension to the clinical understanding of Renuvion and its potential role in comprehensive aesthetic procedures.
• That is why we believe Renuvion should be part of every liposuction procedure, around the world.
• Liposuction addresses fat, but the quality of the tissue and skin left behind is also critical to the final result.

Industry Context

StockSavvy.ai notes that this announcement aligns with the growing demand for minimally invasive aesthetic procedures that offer natural-looking results and improved skin quality. The focus on biological markers and histological evidence strengthens Renuvion's position in a competitive market.

Legal Proceedings

• The Company may incur liabilities and costs from pending or threatened litigations, claims, disputes or investigations.

Stakeholder Impact

• Shareholders may see increased confidence in the company's technology due to positive clinical validation, potentially impacting stock value.
• Patients seeking aesthetic procedures may benefit from improved outcomes and satisfaction with Renuvion treatments.
• Surgeons and healthcare providers may be encouraged to adopt or continue using Renuvion based on the presented scientific evidence.
• Competitors in the surgical aesthetics market may face increased pressure to demonstrate similar clinical efficacy and patient satisfaction.

Next Steps

• Continue to leverage clinical data to support the adoption of Renuvion in comprehensive aesthetic procedures.
• Integrate Renuvion into every liposuction procedure globally, as suggested by management.
• Further research and development to expand the understanding and application of Renuvion and AYON Body Contouring System.

Key Dates

Recommendation

The positive clinical data for Renuvion is a strong endorsement of the technology's efficacy and patient satisfaction, which is a key driver for growth in the aesthetic market. However, the filing does not provide updated financial performance or guidance, and the company's forward-looking statements mention potential risks and uncertainties. Therefore, a 'hold' recommendation is appropriate pending further financial disclosures.

Keywords

Renuvion, skin quality, elastin, helium plasma, radiofrequency, dermal remodeling, plastic surgery, aesthetic procedures